Liberty Capital Management Inc. Has $865,000 Holdings in Johnson & Johnson (NYSE:JNJ)

Liberty Capital Management Inc. lessened its position in Johnson & Johnson (NYSE:JNJ) by 2.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,978 shares of the company’s stock after selling 169 shares during the period. Liberty Capital Management Inc.’s holdings in Johnson & Johnson were worth $865,000 as of its most recent filing with the SEC.

Other hedge funds have also added to or reduced their stakes in the company. IFS Advisors LLC lifted its holdings in shares of Johnson & Johnson by 138.9% in the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock valued at $25,000 after purchasing an additional 100 shares in the last quarter. Highline Wealth Partners LLC bought a new stake in shares of Johnson & Johnson during the 3rd quarter worth approximately $31,000. Bay Harbor Wealth Management LLC acquired a new stake in shares of Johnson & Johnson in the 4th quarter valued at approximately $32,000. RPg Family Wealth Advisory LLC bought a new position in shares of Johnson & Johnson in the third quarter valued at $35,000. Finally, Mowery & Schoenfeld Wealth Management LLC increased its holdings in Johnson & Johnson by 58.7% during the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock worth $40,000 after buying an additional 91 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Ratings Changes

JNJ has been the subject of a number of recent analyst reports. Raymond James cut their price target on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research note on Thursday, January 23rd. Stifel Nicolaus dropped their price objective on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a research note on Thursday, January 23rd. Wolfe Research assumed coverage on Johnson & Johnson in a research note on Friday, November 15th. They set an “outperform” rating and a $190.00 target price for the company. Argus upgraded Johnson & Johnson to a “strong-buy” rating in a research note on Friday, January 24th. Finally, Guggenheim lifted their price objective on shares of Johnson & Johnson from $162.00 to $166.00 and gave the stock a “neutral” rating in a research report on Monday, February 3rd. Nine equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $170.67.

Insider Buying and Selling at Johnson & Johnson

In other news, Director Mark A. Weinberger purchased 1,000 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the transaction, the director now owns 1,000 shares of the company’s stock, valued at approximately $147,220. The trade was a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Down 0.6 %

Shares of JNJ opened at $155.23 on Thursday. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $168.85. The firm’s 50 day moving average is $147.48 and its 200-day moving average is $156.01. The stock has a market capitalization of $373.73 billion, a PE ratio of 23.34, a P/E/G ratio of 2.46 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. The firm had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The company’s revenue was up 5.3% on a year-over-year basis. During the same quarter last year, the company earned $2.29 EPS. Equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.20%. Johnson & Johnson’s payout ratio is 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.